WHY IS IT ESSENTIAL TO KEEP THE PAP?
BECAUSE THEY’RE WORTH IT.1 in 5 women with cervical cancer were missed by screening with HPV-Alone.*1 Pap + HPV (co-testing) empowers you to do everything you can to protect the health of your patients.
WHY IS IT ESSENTIAL TO KEEP THE PAP?
BECAUSE THEY’RE WORTH IT.1 in 5 women with cervical cancer were missed by screening with HPV-Alone.1,2* Pap + HPV (co-testing) empowers you to do everything you can to protect the health of your patients.
Leading cervical cancer screening
Hologic’s Offerings
Our specialized suite of testing tools lead the way in creating a brighter future for women’s healthcare.
ThinPrep® Pap Test
Aptima® HPV test
Aptima® HPV 16/18/45 genotype test
Know the facts
The rate of cervical cancer, which was a leading cause of death among women, has fallen by more than 70 percent since the Pap test was introduced over 50 years ago.6 Previously, cervical cancer was the leading cause of cancer death in women, but now it is the fifteenth most frequent.
The difference is in the results – with HPV-Alone*, you will receive less information with the same collection.
Samples may be collected in FDA approved liquid based cytology medium such as ThinPrep® Pap Test.
Is this the right time to make more drastic changes to screening?
“At no point in the publications describing the new guidelines [2012 consensus guidelines] it is acknowledged that we are now recommending more cancer and more death from cancer than the previously recommended 3-year cotesting provides, and that we are doing so presumably for the purpose of avoiding a cervical treatment that is not associated with detectable increased mortality.”
Choose Pap + HPV
Recent publications representative of US clinical practice showed
Pap + HPV (co-testing) misses the fewest cancers/precursors to cancer:
Recent publications representative of US clinical practice show Pap + HPV (co-testing) misses the fewest cancers/precursors to cancer:
Don’t sacrifice
Comparison of three longitudinal co-testing studies.
Kaiser Permanente Northern California (KPNC): Regional laboratory and Integrated Delivery Network
Quest Diagnostics: National reference laboratory
University of Pittsburgh Medical Center (UPMC): Large academic medical center
“Liquid based cytology (LBC) enhanced co-testing detection of cervical cancer … to a greater extent than previously reported with conventional Pap smear and HPV co-testing.”
ACOG, ASCCP, SGO and USPSTF guidelines recommend:17
For women ages 21-29 years old:16
Screening with cervical cytology alone every 3 years is recommended.
For women ages 30-65 years old:†16
Co-testing with cervical cytology and high-risk HPV testing every 5 years is recommended.
For women ages 65 years and older:16
Do not require screening after adequate prior negative screening results.
In many cases, co-testing is covered by the Affordable Care Act.
Co-testing adoption rates at an all time high
Remaining 18% is primarily Pap-based testing
†Based on a 2019 survey of ObGyns
† There are two additional screening methodologies also recommended in this age group. For more information, see the April 2021 ACOG Practice Advisory.